Internal Eli Lilly Documents Added to Online Archive


Internal Eli Lilly records about the antipsychotic drug Zyprexa have been added to the University of California’s online, publicly accessible Drug Industry Documents Archive (DIDA). The documents first became famous in 2006 when MIA Blogger Jim Gottstein and others made them public. “In this collection are a portion of those produced in a class action court case that alleged Eli Lilly withheld data on adverse effects such as weight gain and diabetes and participated in off-label marketing of the drug,” states the notification from DIDA. “These documents highlight Lilly’s marketing strategy of influencing key opinion leaders and its attempts to control the research, the scientific literature and regulatory product labeling to minimize information on adverse effects.”

“The documents were first obtained and made public in 2006 by, expert consultant Dr. David Egilman, attorney Jim Gottstein, and journalists Philip Dawdy and Alex Berenson,” notes the DIDA post. “After a legal battle over public access, the documents were un-sealed and allowed to remain in the public domain.”

Zyprexa Documents and Tamiflu CSRs Added (Drug Industry Documents Archive Blog, August 18, 2014.)

Drug Industry Documents Archive


  1. The funding of NAMI by multiple pharmaceutical companies was exposed by the investigative magazine Mother Jones in 1999, including that an Eli Lilly & Company executive was then “on loan” to NAMI working out of NAMI headquarters. Also, on December 18, 2003, The New York Times exposed that NAMI had bused scores of protestors to a hearing in Frankfort, Kentucky, took out full page ads in Kentucky newspapers, and sent angry faxes to state officials, all to protest a state panel proposal to exclude the antipsychotic drug Zyprexa from Medicaid’s list of preferred medications. According to the article, “What the advocacy groups did not say at the time was that the buses, ads and faxes were all paid for” by the manufacturer of the antipsychotic drug Zyprexa, Eli Lilly.

    Report comment